Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Basal Bolus Clear all
Completed Not applicable Interventional Results available

Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes

NCT04617795
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Omnipod 5 Automated Insulin Delivery System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 21, 2026, 1:46 PM EDT
Terminated Phase 4 Interventional Results available

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

NCT03511521
View directory record Official record
Conditions
Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Interventions
NPH Insulin, glargine, Insulin Aspart
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 21, 2026, 1:46 PM EDT
Terminated Not applicable Interventional Results available

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

NCT00564018
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin detemir, Glargine, NPH
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 21, 2026, 1:46 PM EDT
Not listed Not applicable Interventional

A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections

NCT01045954
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Lispro Insulin and glargine insulin
Drug
Lead sponsor
Diabetes Care Center
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Salinas, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes

NCT05243628
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
Biological · Device
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Loma Linda, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)

NCT00979628
View directory record Official record
Conditions
Type 2 Diabetes, Hyperglycemia
Interventions
sliding scale regular insulin (SSRI), Basal Bolus, Basal Plus
Drug
Lead sponsor
Guillermo Umpierrez, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Decatur, Georgia • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 21, 2026, 1:46 PM EDT
Terminated Not applicable Interventional

Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM)

NCT04269655
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Cloud-Based Continuous Glucose Monitoring
Device
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 21, 2026, 1:46 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excavatum Repair

NCT02056301
View directory record Official record
Conditions
Pectus Excavatum
Interventions
Hydromorphone, Morphine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 18 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Optimizing Local Anesthetic Concentration for Continuous Lumbar Plexus Nerve Blocks

NCT00912873
View directory record Official record
Conditions
Hip Arthroplasty, Hip Pain
Interventions
0.1% Ropivacaine, 0.4% Ropivacaine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

Transdisciplinary Versus Usual Care for Type1 Diabetes in Adolescence

NCT03557151
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Usual Care, Transdisciplinary Care-In Person & Telehealth
Other · Behavioral
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous TAP Blocks: Relative Effects of a Basal Infusion vs. Repeated Bolus Doses

NCT02662023
View directory record Official record
Conditions
Postoperative Pain
Interventions
Bolus, Basal
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks

NCT02523235
View directory record Official record
Conditions
Post-surgical Pain, Total Knee Arthroplasty, Foot/Ankle Surgery, Catheterization for Postop Analgesia
Interventions
ropivacaine 0.2%
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System

NCT01390259
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Open-Loop, Closed-Loop
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes

NCT00922649
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin Pump therapy
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • San Diego, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 4 Interventional

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

NCT00502138
View directory record Official record
Conditions
IDDM
Interventions
Continuous Pramlintide infusion
Drug
Lead sponsor
University Diabetes & Endocrine Consultants
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

NCT05184868
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
AT247, NovoLog, Fiasp
Drug
Lead sponsor
Arecor Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Results available

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

NCT01215955
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin lispro, Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
33
States / cities
Phoenix, Arizona • Concord, California • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

NCT00612040
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion

NCT02603510
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR342434, insulin lispro
Drug
Lead sponsor
Sanofi
Industry
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Little Rock, Arkansas • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

NCT05785832
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Newport Beach, California • Atlanta, Georgia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients

NCT03436498
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin aspart SAR341402, Insulin aspart
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Little Rock, Arkansas • Denver, Colorado • West Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 21, 2026, 1:46 PM EDT
Enrolling by invitation Phase 4 Interventional

Liposomal Bupivacaine Versus Continuous Peripheral Nerve Blocks for Analgesia Following Ankle Surgery

NCT06995352
View directory record Official record
Conditions
Moderate-to-severely Painful Ankle Surgery
Interventions
Popliteal nerve block including liposomal bupivacaine, Adductor canal nerve block including liposomal bupivacaine, Continuous popliteal nerve block with normal saline, Popliteal nerve block with exclusively unencapsulated bupivacaine, Adductor canal nerve block with exclusively unencapsulated bupivacaine, Continuous popliteal nerve block with unencapsulated bupivacaine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

NCT01814137
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart, insulin degludec, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Goodyear, Arizona • Phoenix, Arizona • Anaheim, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 21, 2026, 1:46 PM EDT
Completed Phase 4 Interventional

Insulin Therapy in the Hospital Comparing Two Protocols

NCT00841919
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glargine insulin, NPH insulin and regular insulin, lispro insulin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Oct 21, 2026, 1:46 PM EDT